fashion -WSS

fashion

author：fashion 2025-10-03 00:03:39 - browse：2

The New York Stock Exchange (NYSE) — Spencer Platt/Getty Images

Biohaven Pharmaceuticals said Wednesday that a new type of experimental medicine reduced levels of a disease-causing immune molecule by up to 37% in an early-stage study of human volunteers — a result that the company called “positive” as a proof of concept but that also fell short of investor expectations.

The drug, called BHV-1300, belongs to a new class of antibody medicines that shuttle harmful proteins to the liver so they can be removed from the body. BHV-1300 is specifically designed to reduce levels of an autoantibody called IgG that is implicated in rheumatoid arthritis, myasthenia gravis, and other autoimmune disorders.

In its Phase 1 study, Biohaven tested four escalating doses of BHV-1300 in healthy volunteers, showing a reduction in levels of IgG of 5%, 15%, 30%, and 37%, respectively, the company said. The reductions in IgG levels, which occurred relatively quickly in just four to five days, did not cause significant, adverse changes in liver enzyme levels, Biohaven added — an important safety check given the mechanism of the drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

hotspot

WSS

He's 19 months old and has one of the world’s rarest diseases

Cancer drug shortages should be causing more outrage

Stem cell biologist probes earliest stages of human development

Drug repurposing or repositioning? The language matters

Immune cells and nerve overgrowth may explain recurring UTI pain

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

hotspot

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

United colonoscopy coverage change 'may cost lives,' doctors say

As demand for Covid shots wanes, Moderna seeks its next success

23andMe had bad news about my health. I wish a person had delivered it

Change Healthcare: What is it, why does its cyberattack matter?

Dobbs anniversary: the lost opportunity of abortion as health care

Harvard's David Sinclair gets blowback over aging

The cancer drug shortage isn’t new — and neither are the solutions

The untold story of TV’s first prescription drug ad

Medical leaders decry Supreme Court decision on affirmative action

Bright Health sells Medicare Advantage business to Molina

entertainment

Readout Newsletter: BridgeBio, Akero, and human embryo models

Fetal cell organoids grown from amniotic fluid, study finds

Medicare drug price negotiation continues, as pharma counteroffers

Immune cells and nerve overgrowth may explain recurring UTI pain

Medical records are filled with copy

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

hotspot

Wikipedia

focus

hotspot